Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency

PHASE4CompletedINTERVENTIONAL
Enrollment

1,132

Participants

Timeline

Start Date

April 3, 2017

Primary Completion Date

July 21, 2020

Study Completion Date

July 21, 2020

Conditions
Iron DeficiencyHeart Failure
Interventions
DRUG

ferric carboxymaltose

FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered

OTHER

Normal saline 0.9%

Normal saline will be administered as a bolus injection.

Trial Locations (16)

1500

Hospital Universitario Austral, Buenos Aires

15208

The Baruch Pade Medical Center, Tiberias

30001

University of Murcia, Murcia

91120

Hadassah Ein Kerem University Medical Center, Jerusalem

169609

National Heart Centre of Singapore Pte, Singapore

05403-900

InCor -Instituto do Coração HCFMUSP, São Paulo

Unknown

Clinical Hospital Center Rijeka, Rijeka

Spedali Civilia di Brescia, Brescia

Vasculair Onderzoek Centrum, Hoorn

Kings College Hospital NHS Foundation, London

0102

Aleksandre Aladashvili Clinic LLC, Tbilisi

1107-2020

American University of Beirut Medical Center, Beirut

50-891

Clinical Military Hospital, Wroclaw

014461

Emergency Clinical Hospital, Bucharest

SE 20502

Skane University Hospital, Malmo

02000

The M.D. Strazhesko Institute of Cardiology, Kyiv

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Worldwide Clinical Trials

OTHER

collaborator

Cytel Inc.

INDUSTRY

lead

Vifor (International) Inc.

INDUSTRY